NetScientific Says FDA Granted PDS0101 Cancer Treatment Fast Track Designation
June 06 2022 - 3:08AM
Dow Jones News
By Anthony O. Goriainoff
NetScientific PLC said Monday that the U.S. Food and Drug
Administration has granted its PDS0101 cancer treatment a Fast
Track designation in combination with Merck & Co.'s Keytruda
therapy.
The London-listed life-sciences, technology, investment and
commercialization company said its portfolio company PDS
Biotechnology Corp. was granted the designation for the treatment
of recurrent or metastatic head and neck cancer.
The company said the designation program is intended to help
develop and expedite the review of drug candidate applications that
can potentially treat serious or life-threatening conditions.
"The FDA fast track designation of PDS0101 provides recognition
that the drug fills an unmet need in a serious condition, with the
purpose to get a drug to patients faster. The board therefore
considers this a significant milestone and value inflection point
for PDS," Chief Executive Ilian Iliev said.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
June 06, 2022 02:53 ET (06:53 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024